Related Experiment Video
Updated: Oct 15, 2025

Transcriptional Analysis by Nascent RNA FISH of In Vivo Trophoblast Giant Cells or In Vitro Short-term Cultures of Ectoplacental Cone Explants
Published on: August 31, 2016
Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2
Meng Sun1,2, Helin Zhang1,2, Min Jiang2,3,4
1Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing 100101, China.
Abstract:
Human trophoblast cell surface antigen 2 (TROP-2) is an important target of tumor therapy, and antibody-drug conjugates with sacituzumab targeting TROP-2 have been approved for the treatment of triple-negative breast cancer. Here, we report the crystal structures of TROP-2-ECD, which can be either cis- or trans-dimers depending on which distinct but overlapping interfaces is used to engage with monomers. The cis- or trans-tetrameric forms of TROP-2 can also be assembled with a non-overlapping interface with either cis- or trans-dimerization, suggesting that cis- and trans-dimers cluster on the cell surface. The binding site of sacituzumab on TROP-2 is mapped to be located on a stretched polypeptide in CPD (Q237-Q252), which is not involved in either cis- or trans-interactions. The present findings will improve understanding of the molecular assembly of TROP-2 on tumor cells and shed light on future design of biologics for tumor therapy.
Insights
Human trophoblast cell surface antigen 2 (TROP-2) forms dimers and tetramers on tumor cells. Sacituzumab’s binding site on TROP-2 is separate from these interactions, informing future cancer therapy designs.
Area of Science:
- Biochemistry
- Structural Biology
- Oncology
Background:
- Human trophoblast cell surface antigen 2 (TROP-2) is a key target in cancer therapy.
- Sacituzumab, an antibody-drug conjugate targeting TROP-2, is approved for triple-negative breast cancer treatment.
Purpose of the Study:
- To determine the crystal structures of TROP-2 extracellular domain (ECD).
- To elucidate the molecular assembly and dimerization/tetramerization interfaces of TROP-2.
- To map the binding site of sacituzumab on TROP-2.
Main Methods:
- X-ray crystallography to determine TROP-2-ECD structures.
- Analysis of distinct interfaces involved in TROP-2 monomer interactions.
- Mapping of the sacituzumab binding epitope on TROP-2.
Main Results:
- TROP-2-ECD forms cis- or trans-dimers via distinct interfaces.
- TROP-2 can assemble into cis- or trans-tetramers through non-overlapping interfaces.
- Sacituzumab binds to a TROP-2 polypeptide region (Q237-Q252) not involved in dimerization/tetramerization.
Conclusions:
- TROP-2 dimers and tetramers likely cluster on tumor cell surfaces.
- Understanding TROP-2 assembly provides insights into its role in tumor biology.
- Findings will guide the rational design of novel TROP-2-targeting biologics for cancer therapy.
Related Concept Videos
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Structure of Cadherins
Protein Translocation Machinery on the ER Membrane
Sec61 protein conducting channel
In eukaryotes, the translocon complex comprises a core heterotrimeric translocator channel called the Sec61 complex. This channel includes three transmembrane proteins, Sec61α, Sec61β, and Sec61γ, and is the largest subunit of the...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...

